On May 28, 2021, Humanigen announced that the company had submitted an application to the FDA requesting Emergency Use Authorization (EUA) for lenzilumab for the treatment of patients hospitalized with COVID-19.

This EUA application followed positive results from the LIVE-AIR Phase 3 clinical trial evaluating the ability of lenzilumab to improve the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.